Breaking Finance News

Peel Hunt disclosed Genedrive Plc (LON:GDR), retaining its price target at 150.00GBX earlier today

Reporting a potential upside of 3%, Peel Hunt hold steady the price target of Genedrive Plc (LON:GDR) at 150.00GBX

On 10/25/2017, Peel Hunt released a statement on Genedrive Plc (LON:GDR) upped the target price from 0.00GBX to 150.00GBX that suggested an upside of 0%.

Having a price of 37.50GBX, Genedrive Plc (LON:GDR) traded 0.00% even on the day. With the last close down -6.08% from the two hundred day average, compared with the Standard & Poor's 500 Index which has increased 0.02% over the same period. GDR has recorded a 50-day average of 35.82GBX and a two hundred day average of 39.93GBX. Trade Volume was down over the average, with 3,340 shares of GDR changing hands under the typical 19,804

Recent Performance Chart

Genedrive Plc (LON:GDR)

Genedrive Plc has with a one year low of 30.00GBX and a one year high of 65.00GBX and has a market capitalization of 0 GBX.

General Company Details For Genedrive Plc (LON:GDR)

Genedrive Plc, formerly Epistem Holdings Plc, is a holding company engaged in molecular diagnostics business. The Company operates through segments, including Preclinical Research Services, Pharmacogenomics Services and Diagnostics. Its geographical segments include the United Kingdom, Europe, the United States of America and Asia. Its Preclinical Research Services segment provides pre-clinical testing services. Its Pharmacogenomic Services segment specializes in molecular measures of biological effect. Its Diagnostics segment is commercializing the Genedrive molecular testing platform. Its Preclinical Research Services activities relate to the testing of drugs for drug development companies. The Preclinical Research Services division has developed a range of models across therapeutic pathways, including oncology, gastrointestinal disease, skin care and wound healing. The Pharmacogenomics Service offers multi system transcriptional profiling and laser capture microscopy.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.